In other drug development news, pharmaceutical company Cosmo said its placebo-controlled phase II trial of rifamycin 1% ...

For the first time, a joint guideline from the American Gastroenterological Association (AGA) and American Association for ...

PPAR agonists, antigen-specific immune tolerance therapies and IBAT inhibitors lead the PBC pipeline as companies target patients with an inadequate response to UDCA.Dublin, Oct. (GLOBE NEWSWIRE) -- ...

For the first time, a joint guideline from the American Gastroenterological Association (AGA) and American Association for ...

US gastroenterology and liver disease associations issued joint guidelines on diagnosing and treating primary biliary ...

The Russian Ministry of Health has added primary biliary cholangitis, a chronic autoimmune liver disease, to the list of orphan diseases. This is stated in a departmental document, which was reviewed ...

Patients with concurrent PBC and osteoporosis do not have an increased risk of major bone fracture vs patients with ...

Seladelpar achieved the highest comparative ranking for biochemical response and ALP normalization in patients with PBC.

A review of 5 investigational therapies with target action dates in November 2026, spanning neurology, gastroenterology, and oncology.

Year-to-date total sales growth of 24.6% at CER1, or 23.0% as reported, with the core portfolio2 achieving sales growth of 24.2%1Further upgraded ...

GSK plc’s GSK key growth story is the expansion of its newer specialty medicines and vaccines, which can help offset pressure from older products and strengthen its revenue base over the long term.